Does Clofarabine treat kidney cancer?


Project Rephetio predicted a probability of 0.950% that Clofarabine (DB00631) treats kidney cancer (DOID:263). This probability represents a 1.63-fold enrichment over the background prevalence of treatment. This prediction is in the 94.9th percentile for Clofarabine and the 95.4th percentile for kidney cancer.

Most supportive network paths

Run the following query to show the 10 paths which contributed most to this prediction. Toggle AUTO-COMPLETE to OFF to only show relationships that are in these paths.

MATCH p0 = (:Compound {identifier: "DB00631"})-[:INCLUDES_PCiC]-(:PharmacologicClass {identifier: "N0000000233"})-[:INCLUDES_PCiC]-(:Compound {identifier: "DB01101"})-[:TREATS_CtD]-(:Disease {identifier: "DOID:263"})
MATCH p1 = (:Compound {identifier: "DB00631"})-[:INCLUDES_PCiC]-(:PharmacologicClass {identifier: "N0000000233"})-[:INCLUDES_PCiC]-(:Compound {identifier: "DB00441"})-[:TREATS_CtD]-(:Disease {identifier: "DOID:263"})
MATCH p2 = (:Compound {identifier: "DB00631"})-[:BINDS_CbG]-(:Gene {identifier: 6241})-[:BINDS_CbG]-(:Compound {identifier: "DB00441"})-[:TREATS_CtD]-(:Disease {identifier: "DOID:263"})
MATCH p3 = (:Compound {identifier: "DB00631"})-[:BINDS_CbG]-(:Gene {identifier: 6240})-[:BINDS_CbG]-(:Compound {identifier: "DB00441"})-[:TREATS_CtD]-(:Disease {identifier: "DOID:263"})
MATCH p4 = (:Compound {identifier: "DB00631"})-[:RESEMBLES_CrC]-(:Compound {identifier: "DB00987"})-[:RESEMBLES_CrC]-(:Compound {identifier: "DB00441"})-[:TREATS_CtD]-(:Disease {identifier: "DOID:263"})
MATCH p5 = (:Compound {identifier: "DB00631"})-[:RESEMBLES_CrC]-(:Compound {identifier: "DB00928"})-[:RESEMBLES_CrC]-(:Compound {identifier: "DB00441"})-[:TREATS_CtD]-(:Disease {identifier: "DOID:263"})
MATCH p6 = (:Compound {identifier: "DB00631"})-[:BINDS_CbG]-(:Gene {identifier: 5422})-[:BINDS_CbG]-(:Compound {identifier: "DB00441"})-[:TREATS_CtD]-(:Disease {identifier: "DOID:263"})
MATCH p7 = (:Compound {identifier: "DB00631"})-[:RESEMBLES_CrC]-(:Compound {identifier: "DB01262"})-[:RESEMBLES_CrC]-(:Compound {identifier: "DB00441"})-[:TREATS_CtD]-(:Disease {identifier: "DOID:263"})
MATCH p8 = (:Compound {identifier: "DB00631"})-[:BINDS_CbG]-(:Gene {identifier: 1633})-[:BINDS_CbG]-(:Compound {identifier: "DB00441"})-[:TREATS_CtD]-(:Disease {identifier: "DOID:263"})
MATCH p9 = (:Compound {identifier: "DB00631"})-[:BINDS_CbG]-(:Gene {identifier: 9429})-[:BINDS_CbG]-(:Compound {identifier: "DB06589"})-[:TREATS_CtD]-(:Disease {identifier: "DOID:263"})
RETURN [p0, p1, p2, p3, p4, p5, p6, p7, p8, p9]

Is this a known treatment?

PharmacotherapyDB v1.0 does not contain an indication between Clofarabine and kidney cancer. No matching clinical trials were found in ClinicalTrials.gov.

Contribution by path


Which paths provided the most support for this prediction? The following table shows the percent contribution of each path. The number of reported paths is limited to 25.

Percent of Prediction Percent of DWPC Metapath Length Verbose Path

24.50%

50.00%

CiPCiCtD

3

Clofarabine–includes–Nucleic Acid Synthesis Inhibitors–includes–Capecitabine–treats–kidney cancer

24.50%

50.00%

CiPCiCtD

3

Clofarabine–includes–Nucleic Acid Synthesis Inhibitors–includes–Gemcitabine–treats–kidney cancer

5.84%

23.70%

CbGbCtD

3

Clofarabine–binds–RRM2–binds–Gemcitabine–treats–kidney cancer

5.84%

23.70%

CbGbCtD

3

Clofarabine–binds–RRM1–binds–Gemcitabine–treats–kidney cancer

5.56%

35.00%

CrCrCtD

3

Clofarabine–resembles–Cytarabine–resembles–Gemcitabine–treats–kidney cancer

5.28%

33.30%

CrCrCtD

3

Clofarabine–resembles–Azacitidine–resembles–Gemcitabine–treats–kidney cancer

5.05%

20.50%

CbGbCtD

3

Clofarabine–binds–POLA1–binds–Gemcitabine–treats–kidney cancer

5.03%

31.70%

CrCrCtD

3

Clofarabine–resembles–Decitabine–resembles–Gemcitabine–treats–kidney cancer

3.11%

12.60%

CbGbCtD

3

Clofarabine–binds–DCK–binds–Gemcitabine–treats–kidney cancer

0.92%

3.72%

CbGbCtD

3

Clofarabine–binds–ABCG2–binds–Pazopanib–treats–kidney cancer

0.84%

3.40%

CbGbCtD

3

Clofarabine–binds–ABCG2–binds–Dactinomycin–treats–kidney cancer

0.65%

2.65%

CbGbCtD

3

Clofarabine–binds–ABCG2–binds–Erlotinib–treats–kidney cancer

0.60%

2.43%

CbGbCtD

3

Clofarabine–binds–ABCG2–binds–Paclitaxel–treats–kidney cancer

0.53%

2.16%

CbGbCtD

3

Clofarabine–binds–ABCG2–binds–Sorafenib–treats–kidney cancer

0.52%

2.09%

CbGbCtD

3

Clofarabine–binds–ABCG2–binds–Vincristine–treats–kidney cancer

0.43%

1.75%

CbGbCtD

3

Clofarabine–binds–ABCG2–binds–Sunitinib–treats–kidney cancer

0.32%

1.31%

CbGbCtD

3

Clofarabine–binds–ABCG2–binds–Doxorubicin–treats–kidney cancer

0.14%

5.84%

CbGpPWpGaD

4

Clofarabine–binds–DCK–participates–Purine salvage–participates–APRT–associates–kidney cancer

0.10%

1.39%

CcSEcCtD

3

Clofarabine–causes–Mouth haemorrhage–causes–Temsirolimus–treats–kidney cancer

0.10%

3.87%

CbGpPWpGaD

4

Clofarabine–binds–RRM1–participates–Fluoropyrimidine Activity–participates–PPAT–associates–kidney cancer

0.09%

1.31%

CcSEcCtD

3

Clofarabine–causes–Mouth haemorrhage–causes–Pazopanib–treats–kidney cancer

0.09%

1.27%

CcSEcCtD

3

Clofarabine–causes–Staphylococcal bacteraemia–causes–Vincristine–treats–kidney cancer

0.09%

1.21%

CcSEcCtD

3

Clofarabine–causes–Capillary leak syndrome–causes–Gemcitabine–treats–kidney cancer

0.08%

3.40%

CbGpPWpGaD

4

Clofarabine–binds–RRM1–participates–Retinoblastoma (RB) in Cancer–participates–HLTF–associates–kidney cancer

0.08%

3.19%

CbGpPWpGaD

4

Clofarabine–binds–RRM2–participates–Fluoropyrimidine Activity–participates–PPAT–associates–kidney cancer

Contribution by metapath


Which types of paths provided the most support for this prediction? The following table shows the percent contribution of each metapath.

Metapath Percent of Prediction Path Count Length Verbose

CiPCiCtD

48.97%

2

3

Compound–includes–Pharmacologic Class–includes–Compound–treats–Disease

CbGbCtD

24.63%

12

3

Compound–binds–Gene–binds–Compound–treats–Disease

CrCrCtD

15.88%

3

3

Compound–resembles–Compound–resembles–Compound–treats–Disease

CcSEcCtD

7.25%

1,134

3

Compound–causes–Side Effect–causes–Compound–treats–Disease

CbGpPWpGaD

2.49%

355

4

Compound–binds–Gene–participates–Pathway–participates–Gene–associates–Disease

CbGeAlD

0.59%

14

3

Compound–binds–Gene–expresses–Anatomy–localizes–Disease

CbGdCrCtD

0.14%

9

4

Compound–binds–Gene–downregulates–Compound–resembles–Compound–treats–Disease

CrCbGaD

0.05%

1

3

Compound–resembles–Compound–binds–Gene–associates–Disease

Contribution by source edge


The source edge of a path refers to its first edge. The following table shows the total contribution of each source edge across all paths. The number of displayed edges is limited to 25.

Source Edge Percent of Prediction Path Count Distinct Metapaths

Clofarabine—includes—Nucleic Acid Synthesis Inhibitors

49.00%

2

1

Clofarabine—binds—RRM1

6.80%

84

4

Clofarabine—binds—RRM2

6.61%

89

4

Clofarabine—resembles—Cytarabine

5.56%

1

1

Clofarabine—binds—POLA1

5.42%

85

3

Clofarabine—resembles—Azacitidine

5.28%

1

1

Clofarabine—binds—ABCG2

5.23%

79

3

Clofarabine—resembles—Decitabine

5.03%

1

1

Clofarabine—binds—DCK

3.81%

53

4

Clofarabine—causes—Bilirubin total increased

0.20%

4

1

Clofarabine—causes—Mouth haemorrhage

0.20%

2

1

Clofarabine—causes—Lymphopenia

0.15%

9

1

Clofarabine—causes—Mucosal inflammation

0.15%

9

1

Clofarabine—causes—Septic shock

0.13%

5

1

Clofarabine—causes—Rash generalised

0.13%

5

1

Clofarabine—causes—Prurigo

0.11%

5

1

Clofarabine—causes—Pericardial effusion

0.10%

5

1

Clofarabine—causes—Febrile neutropenia

0.10%

8

1

Clofarabine—causes—Tumour lysis syndrome

0.09%

4

1

Clofarabine—causes—Staphylococcal bacteraemia

0.09%

1

1

Clofarabine—causes—Multi-organ failure

0.09%

4

1

Clofarabine—causes—Capillary leak syndrome

0.09%

1

1

Clofarabine—causes—Pleural effusion

0.09%

8

1

Clofarabine—causes—Cellulitis

0.09%

9

1

Clofarabine—causes—Blood bilirubin increased

0.08%

9

1

Contribution by target edge


The target edge of a path refers to its last edge. The following table shows the total contribution of each target edge across all paths. The number of displayed edges is limited to 25.

Target Edge Percent of Prediction Path Count Distinct Metapaths

kidney cancer—treats—Gemcitabine

60.68%

92

5

kidney cancer—treats—Capecitabine

24.90%

117

2

kidney cancer—treats—Pazopanib

1.77%

84

2

kidney cancer—treats—Paclitaxel

1.34%

129

2

kidney cancer—treats—Sunitinib

1.27%

111

2

kidney cancer—treats—Temsirolimus

1.12%

93

2

kidney cancer—treats—Dactinomycin

1.11%

42

2

kidney cancer—treats—Erlotinib

1.08%

72

3

kidney cancer—treats—Vincristine

0.98%

65

3

kidney cancer—treats—Sorafenib

0.93%

78

2

kidney cancer—treats—Everolimus

0.89%

115

2

kidney cancer—treats—Doxorubicin

0.70%

134

3

kidney cancer—associates—PPAT

0.42%

11

1

kidney cancer—associates—APRT

0.39%

10

2

kidney cancer—associates—HLTF

0.27%

4

1

kidney cancer—treats—Vinblastine

0.15%

28

2

kidney cancer—associates—TFE3

0.13%

3

1

kidney cancer—localizes—gonad

0.12%

3

1

kidney cancer—localizes—nephron tubule

0.11%

3

1

kidney cancer—localizes—renal system

0.10%

2

1

kidney cancer—associates—PSMD7

0.10%

17

1

kidney cancer—localizes—kidney

0.10%

2

1

kidney cancer—associates—ABCB1

0.09%

11

1

kidney cancer—associates—APAF1

0.09%

5

1

kidney cancer—associates—CDKN1B

0.08%

21

1